Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Belite Bio Inc BLTE

Healthcare Biotechnology
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health... see more

Current News (NDAQ:BLTE)

Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease

GlobeNewswire 1 day ago

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

GlobeNewswire March 31, 2026

Belite Bio to Participate in the Leerink Global Healthcare Conference

GlobeNewswire March 2, 2026

Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

GlobeNewswire March 2, 2026

Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire February 23, 2026

Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)

GlobeNewswire January 29, 2026

Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)

GlobeNewswire January 27, 2026

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

GlobeNewswire December 1, 2025

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

GlobeNewswire December 1, 2025
View More News ››

Opinion & Analysis (NDAQ:BLTE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:BLTE)

Be the first to post on this bullboard.

Oregen Energy Corp

Oregen Energy Corp

Oregen Energy Corp., an energy and resource exploration company, focuses on acquiring and advancing natural resources ...
View More »

Podcasts